 |
Providing
Quality
|
Latest News
2nd June 2008 It is with great regret that we that we announce the recent and sudden death of our colleague and friend Professor Lloyd Kelland on the 23rd May 2008. He will be greatly missed by all at Vivoserve, and will be a great loss to the scientific community at large. We extend our deepest sympathies to his family. A graduate in Pharmacy from the University of Bath (1979). Having obtained his membership of the Royal Pharmaceutical Society, he studied the biological properties of ultraviolet radiation between 1980 and 1983 for his PhD. He then undertook a post-doctoral research Fellowship at the Radiotherapy Research Unit (Royal Marsden Hospital (RMH), Institute of Cancer Research (ICR) London) where he investigated the radiobiological properties of preclinical models of cervical cancer (cell lines and xenografts). Thereafter until 2001 he worked at the Drug Development Section / Cancer Research Campaign Centre for Cancer Therapeutics at ICR/RMH, from 1991 as a Team Leader (Platinum and Drug Evaluation Teams) and Reader in Pharmacology. His role involved the establishment of clinically predictive pre-clinical antitumour models for evaluating potential anticancer drugs, especially platinum compounds. Also models of acquired cisplatin resistance were established and mechanistic studies performed to determine mechanisms of resistance. The platinum project resulted in two drugs entering clinical trials, JM216 (satraplatin) now in phase III trials as the first orally available platinum drug and JM473/ZD0473/AMD473 - a sterically hindered compound possessing activity against cisplatin-resistant tumours. Other areas of study for which he ran pre-clinical pharmacology and mechanistic studies included novel molecularly targeted agents against telomerase, cyclin-dependent kinases, Phosphatidylinositol-3-kinases and Heat Shock Protein 90. He authored more than 160 papers, and over 50 review articles; supervised more than 10 PhD students, was on the editorial board of four international journals and presented at numerous International conferences worldwide. A member of the American Association of Cancer Research, The American Society of Clinical Oncology and the Royal Society of Medicine, he held visiting professorial positions at two London University Institutions: St Georges Hospital Medical School and the London University School of Pharmacy. In 2000 he was awarded a Doctor of Science (DSc) from the University of Bath. From 2001 he has worked as Head of Laboratory/Head of Research at Antisoma PLC, a UK-based biotechnology company running three research Teams: molecular biology, protein production/purification and pharmacology/toxicology and also managing external collaborations covering both small molecule and biological based anticancer drug development. Most recently he became Head of Biology at CRT's Development Laboratories in London. With over 20 years experience in pre-clinical cancer drug development he established an extensive network of International contacts in both academia and industry and was highly respected in the field. |
Vivoserve Corporate OfficeLeicester Business Centre t: +44 (0)870 042 7039 |
